Alaunos Therapeutics, Inc. (TCRT)
NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 2.2100 |
| Open | 2.2000 |
| Bid | 1.8400 x 100 |
| Ask | 2.4700 x 100 |
| Day's range | 2.1100 - 2.2000 |
| 52-week range | 2.0700 - 33.0000 |
| Volume | |
| Avg. volume | 24,639 |
| Market cap | 3.379M |
| Beta (5Y monthly) | -0.54 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -319.9700 |
| Earnings date | 12 Nov 2024 - 18 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireAlaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
Best Response to TCR-T Best Response to TCR-T TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patientshunTR® discovered new HLA class I and class II restricted TCRs that recognize driver mutations, including KRAS and TP53Company continues to explore potential strategic alternatives; cost-savings measures expected to extend cash runaway into the second quar
© 2024 Yahoo. All rights reserved.